NALP3抗体;NALP3 Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     Kynurenic acid/GPR35 axis restricts NLRP3 inflammasome activation and exacerbates colitis in mice with social stress. -BRAIN BEHAVIOR AND IMMUNITY    

  
  

•  

   

     Immunofluorescent analysis of Raw264.7 cells, using NALP3 Antibody.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using NALP3 Antibody.    

  
  

The NALP3 (NACHT, LRR, and PYD domains-containing protein 3) antibody targets the NLRP3 protein, a key component of the NLRP3 inflammasome—a multiprotein complex central to innate immunity. NLRP3 senses pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), triggering caspase-1 activation and subsequent release of pro-inflammatory cytokines IL-1β and IL-18. Dysregulated NLRP3 activation is implicated in autoinflammatory diseases (e.g., cryopyrin-associated periodic syndromes, CAPS), gout, Alzheimer’s disease, and atherosclerosis.

NALP3 antibodies are primarily used as research tools to study inflammasome activation mechanisms and validate NLRP3 expression in disease models. Therapeutically, monoclonal antibodies targeting NLRP3 or its downstream effectors (e.g., anti-IL-1β drugs like canakinumab) aim to suppress excessive inflammation. Direct NLRP3 inhibitors, including antibodies, are under investigation to address conditions driven by inflammasome hyperactivity. Challenges include ensuring specificity to avoid immunosuppression and optimizing delivery to target tissues.

Recent advances highlight NLRP3's role in metabolic and neurodegenerative disorders, expanding potential clinical applications. However, translating NLRP3-targeting antibodies into therapies requires balancing efficacy with safety, given the inflammasome's dual role in host defense and pathologic inflammation.